Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The

MEI Pharma Says Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients Showing Significant Biologic Activity at #ASCO2019

12:00am, Saturday, 01'st Jun 2019

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

12:00am, Sunday, 26'th May 2019

MEI Pharma Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $1.25M Beat $690K Estimate

12:00am, Thursday, 09'th May 2019

— Biotech Stock Picks From Legendary Investor Joseph Edelman

12:00am, Friday, 12'th Apr 2019

MEI Pharma To Present At 29th Annual Oppenheimer Healthcare Conference

12:00am, Tuesday, 12'th Mar 2019

BTIG Research Initiates Coverage On MEI Pharma with Buy Rating

12:00am, Wednesday, 13'th Feb 2019

The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

12:00am, Friday, 08'th Feb 2019

MEI Pharma Q2 EPS $(0.15) Misses $(0.12) Estimate, Sales $2.05M Miss $2.08M Estimate

12:00am, Thursday, 07'th Feb 2019

48 Biggest Movers From Friday

12:00am, Monday, 31'st Dec 2018

H.C. Wainwright Initiates Coverage On MEI Pharma with Buy Rating, Announces $10 Price Target

12:00am, Thursday, 20'th Dec 2018

Mei Pharma Stock News

MEI Pharma up 5% premarket on updated ME-401 data

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at #ICML2019

MEI Pharma: Time To Reload At Key Support Level

MEI Pharma Highlights Updated Data From ME-401 Monotherapy, In Combo With Rituximab Phase 1b Study In Patients With Follicular Lymphoma At ASCO

The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

MEI Pharma Says Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients Showing Significant Biologic Activity at #ASCO2019

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

MEI Pharma Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $1.25M Beat $690K Estimate

— Biotech Stock Picks From Legendary Investor Joseph Edelman

MEI Pharma To Present At 29th Annual Oppenheimer Healthcare Conference

BTIG Research Initiates Coverage On MEI Pharma with Buy Rating

The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

MEI Pharma Q2 EPS $(0.15) Misses $(0.12) Estimate, Sales $2.05M Miss $2.08M Estimate

48 Biggest Movers From Friday

H.C. Wainwright Initiates Coverage On MEI Pharma with Buy Rating, Announces $10 Price Target

Top Fintech Company